These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 19369578)

  • 1. Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones.
    Kaimal R; Song X; Yan B; King R; Deng R
    J Pharmacol Exp Ther; 2009 Jul; 330(1):125-34. PubMed ID: 19369578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes.
    Sugawara A; Takeuchi K; Uruno A; Ikeda Y; Arima S; Sato K; Kudo M; Taniyama Y; Ito S
    Hypertens Res; 2001 May; 24(3):229-33. PubMed ID: 11409645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
    Camp HS; Li O; Wise SC; Hong YH; Frankowski CL; Shen X; Vanbogelen R; Leff T
    Diabetes; 2000 Apr; 49(4):539-47. PubMed ID: 10871190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression.
    Brunmair B; Gras F; Neschen S; Roden M; Wagner L; Waldhäusl W; Fürnsinn C
    Diabetes; 2001 Oct; 50(10):2309-15. PubMed ID: 11574413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of 15d-PGJ2 as an antagonist of farnesoid X receptor: molecular modeling with biological evaluation.
    Xu X; Lu Y; Chen L; Chen J; Luo X; Shen X
    Steroids; 2013 Sep; 78(9):813-22. PubMed ID: 23707573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.
    Al-Alem L; Southard RC; Kilgore MW; Curry TE
    PLoS One; 2011 Jan; 6(1):e16179. PubMed ID: 21283708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel PPARgamma-dependent and independent effects for thiazolidinediones.
    Narce M; Poisson JP
    Curr Opin Lipidol; 2003 Dec; 14(6):651-2. PubMed ID: 14624145
    [No Abstract]   [Full Text] [Related]  

  • 8. Differentiating members of the thiazolidinedione class: a focus on safety.
    Lebovitz HE
    Diabetes Metab Res Rev; 2002; 18 Suppl 2():S23-9. PubMed ID: 11921435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiatherosclerotic effect of farnesoid X receptor.
    Mencarelli A; Renga B; Distrutti E; Fiorucci S
    Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H272-81. PubMed ID: 19028791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of thiazolidinediones on bile acid transport in rat liver.
    Snow KL; Moseley RH
    Life Sci; 2007 Jan; 80(8):732-40. PubMed ID: 17126857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways.
    Abdelkarim M; Caron S; Duhem C; Prawitt J; Dumont J; Lucas A; Bouchaert E; Briand O; Brozek J; Kuipers F; Fievet C; Cariou B; Staels B
    J Biol Chem; 2010 Nov; 285(47):36759-67. PubMed ID: 20851881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
    Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
    Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.
    Eto K; Ohya Y; Nakamura Y; Abe I; Fujishima M
    Eur J Pharmacol; 2001 Jun; 423(1):1-7. PubMed ID: 11438300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.
    Saubermann LJ; Nakajima A; Wada K; Zhao S; Terauchi Y; Kadowaki T; Aburatani H; Matsuhashi N; Nagai R; Blumberg RS
    Inflamm Bowel Dis; 2002 Sep; 8(5):330-9. PubMed ID: 12479648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
    Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE
    Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism.
    Davies GF; Khandelwal RL; Wu L; Juurlink BH; Roesler WJ
    Biochem Pharmacol; 2001 Oct; 62(8):1071-9. PubMed ID: 11597575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.
    Higashi Y; Holder K; Delafontaine P
    J Biol Chem; 2010 Nov; 285(47):36361-8. PubMed ID: 20843793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troglitazone and related compounds: therapeutic potential beyond diabetes.
    Fujiwara T; Horikoshi H
    Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
    Orasanu G; Ziouzenkova O; Devchand PR; Nehra V; Hamdy O; Horton ES; Plutzky J
    J Am Coll Cardiol; 2008 Sep; 52(10):869-81. PubMed ID: 18755353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiazolidinediones: a new class of drugs for the therapy of ischemia-reperfusion injury.
    Naito Y; Yoshikawa T
    Drugs Today (Barc); 2004 May; 40(5):423-30. PubMed ID: 15319797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.